Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
12.05 +0.17 (+1.43%) 15:59 ET [NASDAQ]
12.00 x 1,300 12.01 x 1,100
Realtime by (Cboe BZX)
12.00 x 1,300 12.01 x 1,100
Realtime - - (-) -
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
11.91
Day High
12.32
Open 12.03
Previous Close 11.88 11.88
Volume 784,067 784,067
Avg Vol 1,583,519 1,583,519
Stochastic %K 26.80% 26.80%
Weighted Alpha -54.26 -54.26
5-Day Change -0.49 (-3.95%) -0.49 (-3.95%)
52-Week Range 11.18 - 47.45 11.18 - 47.45
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,343,878
  • Shares Outstanding, K 113,121
  • Annual Sales, $ 0 K
  • Annual Income, $ -317,420 K
  • EBIT $ -344 M
  • EBITDA $ -346 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.00

Options Overview Details

View History
  • Implied Volatility 151.92% ( +31.99%)
  • Historical Volatility 67.99%
  • IV Percentile 98%
  • IV Rank 79.43%
  • IV High 180.95% on 01/08/25
  • IV Low 39.80% on 06/18/24
  • Put/Call Vol Ratio 10.00
  • Today's Volume 11
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 1,646
  • Open Int (30-Day) 1,684

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.88
  • Number of Estimates 8
  • High Estimate -0.82
  • Low Estimate -0.92
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -8.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.18 +6.53%
on 03/11/25
Period Open: 13.91
14.53 -18.06%
on 02/21/25
-2.00 (-14.38%)
since 02/14/25
3-Month
11.18 +6.53%
on 03/11/25
Period Open: 25.73
26.69 -55.38%
on 12/18/24
-13.82 (-53.71%)
since 12/13/24
52-Week
11.18 +6.53%
on 03/11/25
Period Open: 26.68
47.45 -74.90%
on 08/20/24
-14.77 (-55.36%)
since 03/14/24

Most Recent Stories

More News
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

DYN : 12.05 (+1.43%)
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

DYN : 12.05 (+1.43%)
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

DYN : 12.05 (+1.43%)
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

DYN : 12.05 (+1.43%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 56.00 (+2.10%)
DYN : 12.05 (+1.43%)
CRDL : 1.1200 (-2.61%)
AMRX : 8.76 (-0.34%)
NKTR : 0.8968 (+9.98%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 56.00 (+2.10%)
DYN : 12.05 (+1.43%)
CRDL : 1.1200 (-2.61%)
AMRX : 8.76 (-0.34%)
NKTR : 0.8968 (+9.98%)
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

DYN : 12.05 (+1.43%)
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for...

DYN : 12.05 (+1.43%)
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

DYN : 12.05 (+1.43%)
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

DYN : 12.05 (+1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 13.20
2nd Resistance Point 12.92
1st Resistance Point 12.40
Last Price 12.05
1st Support Level 11.59
2nd Support Level 11.31
3rd Support Level 10.79

See More

52-Week High 47.45
Fibonacci 61.8% 33.59
Fibonacci 50% 29.32
Fibonacci 38.2% 25.04
Last Price 12.05
52-Week Low 11.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals